A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
| Condition | Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer |
|---|---|
| Phase | Phase 2 |
| Sponsor | Compass Therapeutics |
| Status | Completed |
| Enrollment | 49 participants |
| Interventions | CTX-009 |
| Start date | Dec 8, 2022 |
| Completion date | May 15, 2025 |
| Results posted | Jul 28, 2026 |
Summary
This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.
Overall Response Rate
| CTX-009 10 mg/kg | 2 Participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- CryoBalloon Ablation for Treatment of Duodenal Adenomas — Johns Hopkins University
- Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refract — Jennerex Biotherapeutics
- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III — National Cancer Institute (NCI)
- Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps — National Cancer Institute (NCI)
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal — National Cancer Institute (NCI)
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating — National Cancer Institute (NCI)